Multi epitope assay

Patent metadata

Field	Value
Publication number	US-9612236-B2
Application number	US-201113704258-A
Country	US
Kind code	B2
Filing date	Jun 14, 2011
Priority date	Jun 17, 2010
Publication date	Apr 4, 2017
Grant date	Apr 4, 2017

Abstract

The present invention is related to a method for detection of a biological target in an affinity assay, the method comprising the steps of providing a biological sample volume containing the biological target, adding a first capturing moiety to the biological sample volume comprising the biological target, wherein the first capturing moiety is adhered to a particle, concentration of the captured biological target into an elution volume that is smaller than the biological sample volume in step a), cleavage of the first capturing moiety or the biological target from the particle and direct or indirect detection and/or quantification of the biological target in a sandwich or competitive affinity assay format, wherein the biological target is associated with at least one capturing moiety, preferably at least two capturing moieties.

First claim

The invention claimed is:

1. A method for detecting prostate-specific antigen in an affinity assay, the method comprising the steps of:
a) providing a biological sample volume containing the prostate-specific antigen at a concentration of from at 4 to 10 ng/ml;
b) adding PSA-10 antibody capturing moiety to the biological sample volume, wherein the PSA-10 antibody capturing moiety captures the prostate-specific antigen and is adhered to a magnetic particle, wherein the PSA-10 antibody capturing moiety is linked to the particle via a linker comprising a DNA linker consisting of 48 base pairs of double stranded DNA followed by 10 bases of single stranded DNA, wherein the DNA is digestable by a DNAse and cleavable for specific elution with EcoRI;
c) concentrating the captured prostate-specific antigen by magnetic particle separations into an elution volume of less than 5 μL that is at least eighty times smaller than the biological sample volume in step a) in a time of fifteen minutes;
d) cleaving the prostate-specific antigen from the particle, wherein at least 30% of the prostate-specific antigen is cleaved from the particle using a DNAse or EcoRI;
e) binding the prostate-specific antigen to a modified PSA-36 antibody capturing moiety associated with a reagent and to a modified PSA-66 antibody capturing moiety comprising a tag, wherein a portion of the PSA-10 antibody capturing moiety that was cleaved from the particle binds to one of the modified antibodies, and
f) at least one of detecting and quantifying the prostate-specific antigen in an affinity assay format, wherein the tag binds to a fourth capturing moiety on a detection surface.

2. The method according to claim 1 , wherein the reagent is selected from the group consisting of;
a radioisotope,
a solid phase,
a fluorescent, phosphorescent, or chemiluminescent dye,
an enzyme or enzyme substrate,
a nucleic acid sequence or peptide,
a colloid or nanoparticle, and
a polymer or macromolecule.

3. The method according to claim 1 , wherein the at least one of detecting and quantifying step e) is performed according to a method selected from the group consisting of:
an optical detection,
an enzyme reaction,
nucleic-acid amplification techniques,
a magnetic detection,
a sonic detection, and
an electrical detection.

4. The method according to claim 1 , wherein the tag comprises biotin and the fourth capturing moiety comprises either avidin or streptavidin.

5. A method for detecting prostate-specific antigen in an affinity assay, the method comprising the steps of:
a) providing a biological sample volume containing the prostate-specific antigen at a concentration of from at 4 to 10 ng/ml;
b) adding PSA-10 antibody capturing moiety to the biological sample volume, wherein the PSA-10 antibody capturing moiety captures the prostate-specific antigen and is adhered to a magnetic particle, wherein the PSA-10 antibody capturing moiety is linked to the particle via a linker comprising a DNA linker consisting of 48 base pairs of double stranded DNA followed by 10 bases of single stranded DNA, wherein the DNA is digestable by a DNAse and cleavable for specific elution with EcoRI;
c) concentrating the captured prostate-specific antigen by magnetic particle separations into an elution volume of less than 5 μL that is at least eighty times smaller than the biological sample volume in step a) in a time of fifteen minutes;
d) cleaving the prostate-specific antigen from the particle, wherein at least 30% of the prostate-specific antigen is cleaved from the particle and wherein the cleavage is enzymatic;
e) binding the prostate-specific antigen to a modified PSA-36 antibody capturing moiety associated with a reagent and to a modified PSA-66 antibody capturing moiety comprising a tag, wherein a portion of the PSA-10 antibody capturing moiety that was cleaved from the particle binds to one of the modified antibodies, and
f) at least one of detecting and quantifying the prostate-specific antigen in an affinity assay format, wherein the tag binds to a fourth capturing moiety on a detection surface.

6. A method for detecting prostate-specific antigen in an affinity assay, the method comprising the steps of:
a) providing a biological sample volume containing the prostate-specific antigen at a concentration of from at 4 to 10 ng/ml;
b) adding PSA-10 antibody capturing moiety to the biological sample volume, wherein the PSA-10 antibody capturing moiety captures the prostate-specific antigen and is adhered to a magnetic particle, wherein the PSA-10 antibody capturing moiety is linked to the particle via a first entity for attachment to a particle comprising a DNA linker, wherein the DNA is digestable by a DNAse and cleavable for specific elution with EcoRI;
c) concentrating the captured prostate-specific antigen by magnetic particle separations into an elution volume of less than 5 μL that is at least eighty times smaller than the biological sample volume in step a) in a time of fifteen minutes;
d) cleaving the prostate-specific antigen from the particle, wherein at least 30% of the prostate-specific antigen is cleaved from the particle using a second entity for the cleavage of the attachment to the particle;
e) binding the prostate-specific antigen to a modified PSA-36 antibody capturing moiety associated with a reagent and to a modified PSA-66 antibody capturing moiety comprising a third entity for attachment to a detection surface, wherein a portion of the PSA-10 antibody capturing moiety that was cleaved from the particle binds to one of the modified antibodies, and
f) at least one of detecting and quantifying the prostate-specific antigen in an affinity assay format, wherein the third entity binds to a fourth capturing moiety on a detection surface.

Assignees

• Sabatte Gwenola
• Prins Menno Willem Jose
• Evers Toon Hendrik
• Hardeman Wilhelmina Maria
• Orsel Joukje Garrelina
• Koninklijke Philips Nv

Inventors

• Sabatte Gwenola
• Prins Menno Willem Jose
• Evers Toon Hendrik
• Hardeman Wilhelmina Maria
• Orsel Joukje Garrelina

Classifications

• G01N33/5306 Primary

  Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding · CPC title

• G01N33/54333

  Modification of conditions of immunological binding reaction, e.g. use of more than one type of particle, use of chemical agents to improve binding, choice of incubation time or application of magnetic field during binding reaction · CPC title

• G01N33/54306 Primary

  Solid-phase reaction mechanisms · CPC title